Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Fusobacterium nucleatum (F. nucleatum) promotes intestinal tumor growth and its relative
abundance varies greatly among patients with CRC, suggesting the presence of unknown …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

We identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-
infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer. We …

Colorectal cancer (CRC) results from the progressive accumulation of multiple genetic and
epigenetic aberrations within cells. The progression from colorectal adenoma to carcinoma …

The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% develo** colorectal liver metastases (CRLM) during the course of their …

The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …

It is unknown whether the human immune system frequently mounts a T cell response
against mutations expressed by common epithelial cancers. Using a next-generation …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …